ASR Rulemaking Will Hinge On Risk Levels; AmpliChip Clarification Awaited
This article was originally published in The Gray Sheet
Executive Summary
Clarification on the regulation of microarrays as analyte-specific reagents likely will be provided in a letter from FDA to Roche Molecular Diagnostics within the next two weeks